Doripenem

Doripenem C화학적 특성, 용도, 생산

개요

Doripenem monohydrate is an ultra-broad-spectrum injectable β-lactam antibiotic and belongs to the subgroup of carbapenems. It was introduced by Shionogi Co. of Japan under the brand name Finibax in 2005 and is being marketed outside Japan by Johnson & Johnson. Doripenem act by decreases the process of cell wall growth, which eventually leads to elimination of the infectious cell bacteria together. It is used for treatment of bacterial respiratory and urinary tract infections. Doripenem is a 1β-methyl carbapenem derivative, and it is the fourth analog to be marketed in this series following the launch of meropenem, biapenem, and ertapenem in previous years. The introduction of a 1β-methyl group to the carbapenem skeleton enhances metabolic stability to renal dehydropeptidase-1 (DHP-1) and leads to improved antibacterial potency.

화학적 성질

Doripenem white to somewhat yellowish crystalline powder which is moderately soluble in water, slightly soluble in methanol, and virtually insoluble in ethanol. Doripenem is also solution in N,N-dimethylformamide. The chemical configuration of doripenem’s has 6 asymmetrical carbon atoms (6 stereocenters) and is most commonly supplied as one pure isomer. In terms of doripenem for injection, the crystallized powered drug can form a monohydrate when mixed with water.

용도

Doripenem hydrate is used to treat complicated urinary infection including Pyelonephritis caused by E.coli. Doripenem hydrate is promoted in the United States as DORIBAX(R). This drug is synthesized from p-nitrobenzyl-protected enolphosphate 2b and N-(p-nitrobenzyloxycarbonyl)-protected aminomethylpyrrolidine.

상표명

Doribax,Finibax

Antimicrobial activity

Doripenem have a broad spectrum of bacterial activity including both gram-positive and gram-negative bacteria but it is not active against MRSA. It is stable against β-lactamases including those with extended spectrum, but it is susceptible to the action of carbapenemases (Mandell, 2009). Thus it can be used in the treatment of infections such as: complex abdominal infections, pneumonia within the setting of a hospital, and complicated infections of the urinary tract including kidney infections with septicemia. Doripenem is also more active against Pseudomonas aeruginosa then other carbapenems.

Pharmacokinetics

Cmax 500 mg intravenous infusion (1 h): c. 23 mg/L after 1 h
500 mg intravenous infusion (4 h): c. 8 mg/L
Plasma half-life: 1 h
Volume of distribution: 16.8 L (steady state)
Plasma protein binding: 8.1%
Absorption and distribution
Doripenem is not absorbed after oral administration. It penetrates well into most tissues and fluid, achieving concentrations matching or exceeding those required to inhibit most susceptible bacteria at the site of infection for the approved indications.
Metabolism and excretion
Metabolism of doripenem to the microbiologically inactive ring-opened metabolite occurs primarily by renal dehydropeptidase. Based on area under the concentration–time curve (AUC) values in plasma following a single 500 mg dose in healthy volunteers, 18% appears as metabolite and the rest as unchanged drug.
Excretion is primarily by the renal route. Within 24 h after dosing, 78.7% and 18.5% of the dose was recovered in urine as unchanged drug and the ring-opened metabolite, respectively. After administration of radiolabeled doripenem, 0.7% of the total radioactivity was recovered in feces after 1 week.

Clinical Use

Doripenem is indicated for use for the treatment of intra-abdominal infections, and complicated urinary tract infections.
Complicated urinary tract infections, including pyelonephritis
Nosocomial pneumonia, including ventilator-associated pneumonia (Europe)

부작용

The most commonly reported adverse effects of doripenem include pain or swelling at the injection site, nausea, headache, and diarrhea.
Seizure and central nervous system (CNS) side effects are observed rarely (<1%), though headache is reported by 2.3% of patients. Other common drug-related adverse reactions are diarrhea (2.0%), nausea (1.9%), anemia (1.4%) and phlebitis (1.4%). Hypersensitivity reactions related to intravenous administration of the study drug and Clostridium difficile colitis occurred at a rate of less than 1%. However, patients with a history of hypersensitivity reactions to other β-lactam agents should be treated cautiously.

Mode of action

Doripenem's bactericidal function is due to its inhibition of the third stage of bacterial cell wall synthesis. Binding to penicillin-binding proteins weakens the cell wall and leads to cell death due to lysis of the cell wall.
Doripenem is effective against both grampositive and gramnegative aerobic bacteria.It may be more potent in vitro against Pseudomonas aeruginosa than meropenem.

Doripenem 준비 용품 및 원자재

원자재

준비 용품

Doripenem 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Shaanxi Haibo Biotechnology Co., Ltd	+undefined18602966907	qinhe02@xaltbio.com	China	1000	58
Shaanxi TNJONE Pharmaceutical Co., Ltd	+8618740459177	sarah@tnjone.com	China	1142	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21688	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	967	58
Hebei Guanlang Biotechnology Co., Ltd.	+86-19930503282	alice@crovellbio.com	China	8829	58
Chongqing Chemdad Co., Ltd	+86-023-61398051 +8613650506873	sales@chemdad.com	China	39916	58
Shanghai Yingrui Biopharma Co.,Ltd	21-33585366	export01@shyrchem.com	CHINA	1320	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49391	58

Doripenem 관련 검색: